<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000922</url>
  </required_header>
  <id_info>
    <org_study_id>VIAJECT™-010JM</org_study_id>
    <nct_id>NCT01000922</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro</brief_title>
  <official_title>A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a Standardized Meal in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal
      injections of individual doses of the study insulins.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the maximal post prandial blood glucose concentration and the time to maximal post prandial glucose concentration between the different treatments</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the ppGlucmax for all treatments, the ppTGluc-max, the AUCGluc 0-180 and the AUCGluc 0-360, CGluc-baseline for all treatments.</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Regular Human Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIAject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIAject 50%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIAject/Insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine/VIAject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Human Insulin</intervention_name>
    <description>Individual dose of RHI administered subcutaneously</description>
    <arm_group_label>Regular Human Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lispro</intervention_name>
    <description>Individual dose of lispro administered subcutaneously</description>
    <arm_group_label>Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIAject</intervention_name>
    <description>Individual dose of VIAject administered subcutaneously</description>
    <arm_group_label>VIAject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIAject 50%</intervention_name>
    <description>Individual dose of VIAject 50% administered subcutaneously</description>
    <arm_group_label>VIAject 50%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIAject/Insulin Glargine</intervention_name>
    <description>VIAject mixed wiht insulin glargine and administered subcutaneously</description>
    <arm_group_label>VIAject/Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine/VIAject</intervention_name>
    <description>Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously</description>
    <arm_group_label>Insulin Glargine/VIAject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Established diagnosis of type 1 diabetes for not less than 5 years

          2. HbA1c values of not more than 9%

          3. Age: 19 to 70 years

          4. Sex: Male or Female

          5. Body Mass Index: 18 - 28 kg/m2

          6. Informed consent must be obtained in writing for all volunteers.

        Exclusion Criteria:

          1. Type 2 Diabetes mellitus.

          2. History of hypersensitivity to any of the components in the study medication.

          3. History of severe or multiple allergies.

          4. Treatment with any other investigational drug in the last 1 month before study entry.

          5. Treatment with any concomitant medication that in the judgment of the investigator.
             would interfere with the study results.

          6. Progressive disease likely to prove fatal (e.g. malignancies).

          7. Current drug or alcohol abuse, or a history which in the opinion of the Investigator
             will impair subject safety or protocol compliance.

          8. Having a significant cardiovascular, respiratory, gastrointestinal, hepatic, renal,
             neurological, psychiatric and/or hematological disease as evaluated by the
             investigator.

          9. Blood donation within the last 30 days.

         10. A women who is lactating.

         11. Pregnant women or women intending to become pregnant during the study.

         12. A sexually active woman of childbearing age not actively practicing birth control by
             using a medically accepted device or therapy.

         13. Positive Serology for HIV, Hepatitis B or Hepatitis C.

         14. Abnormal ECG, safety lab or physical examination results that are deemed clinically
             significant by the investigator.

         15. A lack of compliance or other reasons which, in the opinion of the investigator,
             prevent the participation of the subject in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Hompesch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc. (PICR)</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <disposition_first_submitted>July 28, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 29, 2015</disposition_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mealtime Insulin</keyword>
  <keyword>Rapid acting insulin</keyword>
  <keyword>Ultra fast VIAject</keyword>
  <keyword>prandial insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

